Andre Turenne, Matchpoint Therapeutics CEO (Jen Randall Photography)

For­mer Voy­ager CEO An­dre Turenne makes a come­back with At­las-backed co­va­lent drug biotech 

Last May, An­dre Turenne re­signed from his CEO and pres­i­dent posts at Voy­ager to “pur­sue oth­er op­por­tu­ni­ties” af­ter the neu­ro­science biotech, once one half …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.